Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$11.79 USD
-0.35 (-2.88%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $11.76 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SAVA 11.79 -0.35(-2.88%)
Will SAVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SAVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SAVA
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
SAVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
Brian's Big Idea on Low Priced Stocks
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
Other News for SAVA
Cassava Sciences Issues Statement on Former Science Advisor
Cassava continues selloff, shares now down 50% to $9.56
Cassava sinks after grand jury indicts co-lead scientist on Alzheimer's drug
Cassava Sciences plunges 40% after simufilam researcher indicted on fraud charges
Cassava sinks 36% to $12.16 after DOJ charges co-developer of drug